Literature DB >> 21178586

Diagnosis and therapeutic management in a patient with type 2B-like acquired von Willebrand syndrome.

Ralf Karger1, Monika Weippert-Kretschmer, Ulrich Budde, Volker Kretschmer.   

Abstract

Acquired von Willebrand syndrome (AVWS) usually mimics von Willebrand disease (VWD) type 1 or 2A. However, in rare cases, the characteristics of other VWD types can predominate in AVWS that might require careful consideration of differential treatment options. The diagnosis and the treatment of a case of type 2B-like AVWS are discussed. Diagnosis of AVWS was ascertained by determining ristocetin cofactor activity, ristocetin-induced platelet aggregation, von Willebrand factor antigen, collagen binding and characterization of von Willebrand factor (VWF) multimers. Inhibitor presence was sought through mixing experiments, the Bethesda method, and calculation of the in-vivo recovery and plasma half-life of VWF after administration of factor VIII/VWF concentrate. Mutations in the A1 domain of VWF were ruled out by sequencing of exon 28 of the VWF gene. A 34-year-old male patient, putatively diagnosed with type 2B VWD, and undergoing laparoscopic cholecystectomy, did not respond adequately to perioperative hemostatic treatment with desmopressin and high doses of factor VIII/VWF concentrate, requiring the administration of recombinant activated factor VII. Further diagnostic workup revealed AVWS mimicking type 2B VWD, most likely owing to an autoantibody developed in the course of underlying monoclonal gammopathy of undetermined significance. The presence of AVWS should be considered before a diagnosis of type 2B VWD is made, especially in patients with a history atypical for inherited disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21178586     DOI: 10.1097/MBC.0b013e328342486a

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  4 in total

1.  Type 2B-like acquired von Willebrand syndrome.

Authors:  Toshio Shigekiyo; Etsuko Sekimoto; Atsuhisa Shirakami; Hiroshi Yamaguchi; Hironobu Shibata; Shuji Ozaki; Kazuya Kanda; Seiya Saito; Nobuo Satake; Osamu Fujino
Journal:  Int J Hematol       Date:  2011-09-30       Impact factor: 2.490

2.  Perioperative intravenous immunoglobulin treatment in a patient with severe acquired von Willebrand syndrome: case report and review of the literature.

Authors:  Eva Jennes; Dorothee Guggenberger; Rainer Zotz; Lora Thompson; Tim H Brümmendorf; Steffen Koschmieder; Edgar Jost
Journal:  Clin Case Rep       Date:  2017-03-30

Review 3.  Acquired von Willebrand syndrome: focused for hematologists.

Authors:  Massimo Franchini; Pier Mannuccio Mannucci
Journal:  Haematologica       Date:  2020-06-18       Impact factor: 9.941

4.  Utility of Bruton's Tyrosine Kinase Inhibitors in Light Chain Amyloidosis Caused by Lymphoplasmacytic Lymphoma (Waldenström's Macroglobulinemia).

Authors:  Maroun Bou Zerdan; Jason Valent; Maria Julia Diacovo; Karl Theil; Chakra P Chaulagain
Journal:  Adv Hematol       Date:  2022-01-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.